Taysha Gene Therapies (TSHA) Total Debt (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Total Debt data on file, last reported at $49.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 15.33% year-over-year to $49.0 million; the trailing twelve-month figure through Mar 2026 stood at $49.0 million (up 15.33% YoY), and the FY2025 full-year result was $50.1 million, up 14.03% from the prior year.
• Total Debt eased to $49.0 million in Q1 2026, from $50.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $50.9 million in Q3 2025 to a low of $37.4 million in Q1 2022.
• A 5-year average of $41.5 million and a median of $40.5 million in 2023 frame the typical range for Total Debt.
• Across the five-year window, Total Debt jumped 35.82% in 2022 and dropped 1.35% in 2024, its largest moves.
• Tracing TSHA's Total Debt over 5 years: stood at $38.0 million in 2022, then grew by 6.69% to $40.5 million in 2023, then grew by 8.48% to $43.9 million in 2024, then rose by 14.03% to $50.1 million in 2025, then fell by 2.29% to $49.0 million in 2026.
• Business Quant data shows TSHA's Total Debt at $49.0 million in Q1 2026, $50.1 million in Q4 2025, and $50.9 million in Q3 2025.